Poly Medicure Limited is a prominent India-based manufacturer and exporter specializing in plastic medical disposables and surgical devices. With a strong focus on innovation and quality, the company has established itself as a leading player in the global healthcare industry.
In this article, we delve into the comprehensive details of Poly Medicure Limited, exploring its product range, manufacturing processes, market presence, and commitment to advancing medical technology for the betterment of healthcare worldwide.
About Poly Medicure
Poly Medicure Limited boasts a diverse product portfolio, focusing on plastic medical disposables and surgical items. With over 130 SKUs spread across nine distinct product verticals, the company is a key exporter in the global healthcare sector. Revenue distribution highlights a significant emphasis on consumables, constituting 51% of the revenue, followed by equipment at 40%, implants at 5%, and reagents at 4%.
Across various categories, Poly Medicure dominates in infusion therapy, accounting for 70% of its revenue, with notable contributions from blood management and collection, surgery and wound drainage, anesthesia and respiratory products, urology items, and others. Facilitating its widespread reach, the company boasts a robust distribution network, comprising over 260 distributors across India. This network effectively connects Poly Medicure to more than 5,000 private and government healthcare institutions, including hospitals and nursing homes, ensuring extensive accessibility to its quality medical solutions nationwide.
Below are the trading platforms that you can use to purchase Poly Medicure shares:
➤ Zerodha
➤ Upstox
➤ Groww
➤ AngelOne
➤ ICICIDirect
| When | Maximum Price | Minimum Price |
| April 2024 | 1,702.08 | 1,480.07 |
| May 2024 | 1,676.93 | 1,458.20 |
| June 2024 | 1,737.30 | 1,510.69 |
| July 2024 | 1,719.92 | 1,495.58 |
| August 2024 | 1,788.72 | 1,555.41 |
| September 2024 | 1,860.27 | 1,617.62 |
| October 2024 | 1,823.79 | 1,585.91 |
| November 2024 | 1,878.51 | 1,633.48 |
| December 2024 | 1,925.47 | 1,674.32 |
Poly Medicure’s share price targets for 2024 indicate a steady upward trajectory, with maximum prices ranging from ₹1,702.08 in April to ₹1,925.47 in December. The minimum prices also reflect positive growth, varying from ₹1,480.07 to ₹1,674.32 over the same period. With a current market capitalization of ₹15,126 crore and a stock price of ₹1,576 as of April 1st, 2024, the company’s stock exhibits notable volatility, with highs reaching ₹1,729 and lows at ₹921.
Additionally, the stock demonstrates a price-to-earnings ratio of 60.8, a book value of ₹139, and a dividend yield of 0.19%. Moreover, Poly Medicure boasts an impressive return on capital employed (ROCE) at 18.3% and return on equity (ROE) at 14.8%, with a face value of ₹5.00
| When | Maximum Price | Minimum Price |
| January 2025 | 1,963.98 | 1,510.75 |
| February 2025 | 2,014.34 | 1,549.49 |
| March 2025 | 2,092.90 | 1,609.92 |
| April 2025 | 2,051.86 | 1,578.35 |
| May 2025 | 1,992.10 | 1,532.38 |
| June 2025 | 2,081.74 | 1,601.34 |
| July 2025 | 2,040.92 | 1,569.94 |
| August 2025 | 2,104.04 | 1,618.49 |
| September 2025 | 2,177.68 | 1,675.14 |
| October 2025 | 2,234.30 | 1,718.70 |
| November 2025 | 2,290.16 | 1,761.66 |
| December 2025 | 2,347.42 | 1,805.70 |
Poly Medicure’s projected share price targets for 2025 show a consistent upward trend, with maximum prices escalating from ₹1,963.98 in January to ₹2,347.42 in December. Conversely, minimum prices also demonstrate growth, ranging from ₹1,510.75 to ₹1,805.70 over the same period.
Notably, the company derives approximately 70% of its revenues from exports, with significant growth stemming from the European Subcontinent, underscoring its global market presence across over 110 countries.
| When | Maximum Price | Minimum Price |
| January 2026 | 2,417.84 | 1,859.88 |
| February 2026 | 2,479.83 | 1,907.56 |
| March 2026 | 2,576.55 | 1,981.96 |
| April 2026 | 2,526.03 | 1,943.10 |
| May 2026 | 2,452.45 | 1,886.50 |
| June 2026 | 2,562.81 | 1,971.40 |
| July 2026 | 2,512.56 | 1,932.74 |
| August 2026 | 2,590.27 | 1,992.52 |
| September 2026 | 2,680.93 | 2,062.25 |
| October 2026 | 2,750.63 | 2,115.87 |
| November 2026 | 2,819.40 | 2,168.77 |
| December 2026 | 2,889.89 | 2,222.99 |
Poly Medicure’s anticipated share price targets for 2026 demonstrate a continued growth trajectory, with maximum prices ranging from ₹2,417.84 in January to ₹2,889.89 in December, and minimum prices varying from ₹1,859.88 to ₹2,222.99 over the same period.
The company’s robust manufacturing capabilities comprise eight facilities worldwide, including five in India, and one each in China, Egypt, and Italy. Additionally, Poly Medicure holds a 23% economic interest in an associate company, ULTRAMED, which operates the facility in Egypt.
| When | Maximum Price | Minimum Price |
| January 2027 | 2,947.68 | 2,267.45 |
| February 2027 | 3,023.26 | 2,325.59 |
| March 2027 | 3,141.17 | 2,416.29 |
| April 2027 | 3,079.58 | 2,368.91 |
| May 2027 | 2,989.88 | 2,299.91 |
| June 2027 | 3,124.43 | 2,403.41 |
| July 2027 | 3,063.17 | 2,356.28 |
| August 2027 | 3,157.90 | 2,429.16 |
| September 2027 | 3,268.43 | 2,514.18 |
| October 2027 | 3,353.41 | 2,579.54 |
| November 2027 | 3,437.24 | 2,644.03 |
| December 2027 | 3,523.17 | 2,710.13 |
Poly Medicure’s projected share price targets for 2027 continue to illustrate an upward trend, with maximum prices climbing from ₹2,947.68 in January to ₹3,523.17 in December, and minimum prices ranging from ₹2,267.45 to ₹2,710.13 over the same period.
The company’s commitment to innovation is evident through its sole R&D facility in Faridabad, India, boasting over 300 patents and 190+ pending applications. Notably, Poly Medicure allocated approximately ₹12 crores (2% of revenues) towards R&D in FY20, compared to ₹10 crores in FY19.
| When | Maximum Price | Minimum Price |
| January 2028 | 3,593.64 | 2,764.34 |
| February 2028 | 3,685.78 | 2,835.22 |
| March 2028 | 3,829.53 | 2,945.79 |
| April 2028 | 3,754.44 | 2,888.03 |
| May 2028 | 3,645.09 | 2,803.91 |
| June 2028 | 3,809.12 | 2,930.09 |
| July 2028 | 3,734.43 | 2,872.64 |
| August 2028 | 3,849.92 | 2,961.48 |
| September 2028 | 3,984.67 | 3,065.13 |
| October 2028 | 4,088.27 | 3,144.83 |
| November 2028 | 4,190.48 | 3,223.45 |
| December 2028 | 4,295.24 | 3,304.03 |
In 2028, Poly Medicure’s share price targets show a range between ₹2,764.34 and ₹4,295.24, reflecting a potential upward trajectory. However, the company encounters formidable competition both globally, contending with multinational corporations like Baxter, Becton Dickinson, and Boston Scientific, and domestically, where it faces challenges from unorganized players in the market.
Despite this competition, Poly Medicure’s strategic positioning and focus on innovation continue to drive its growth in the healthcare sector.
| When | Maximum Price | Minimum Price |
| January 2029 | 4,381.15 | 3,370.11 |
| February 2029 | 4,493.48 | 3,456.53 |
| March 2029 | 4,668.73 | 3,591.33 |
| April 2029 | 4,577.19 | 3,520.91 |
| May 2029 | 4,443.87 | 3,418.36 |
| June 2029 | 4,643.84 | 3,572.19 |
| July 2029 | 4,552.79 | 3,502.15 |
| August 2029 | 4,693.60 | 3,610.46 |
| September 2029 | 4,857.87 | 3,736.82 |
| October 2029 | 4,984.18 | 3,833.98 |
| November 2029 | 5,108.78 | 3,929.83 |
| December 2029 | 5,236.50 | 4,028.08 |
- January 2029: ₹3,370.11(Minimum)
- December 2029: ₹5,236.50 (Maximum)
| When | Maximum Price | Minimum Price |
| January 2030 | 5,341.23 | 4,108.64 |
| February 2030 | 5,478.19 | 4,213.99 |
| March 2030 | 5,691.83 | 4,378.33 |
| April 2030 | 5,580.23 | 4,292.48 |
| May 2030 | 5,417.70 | 4,167.46 |
| June 2030 | 5,661.50 | 4,355.00 |
| July 2030 | 5,550.49 | 4,269.60 |
| August 2030 | 5,722.15 | 4,401.65 |
| September 2030 | 5,922.43 | 4,555.71 |
| October 2030 | 6,076.41 | 4,674.16 |
| November 2030 | 6,228.32 | 4,791.01 |
| December 2030 | 6,384.03 | 4,910.79 |
- January 2030: ₹4,108.64 (Minimum)
- December 2030: ₹6,384.03 (Maximum)
Financial Condition of Poly Medicure: Last 5 years
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Sales (Rs. Crores) | 610 | 687 | 785 | 922 | 1,115 |
| Expenses (Rs. Crores) | 479 | 520 | 569 | 707 | 847 |
| Operating Profit (Rs. Crores) | 131 | 166 | 216 | 215 | 267 |
| Other Income (Rs. Crores) | 20 | 21 | 22 | 40 | 38 |
| Interest (Rs. Crores) | 14 | 20 | 11 | 6 | 11 |
| Depreciation (Rs. Crores) | 37 | 41 | 48 | 54 | 57 |
| Profit before tax (Rs. Crores) | 100 | 126 | 180 | 195 | 237 |
| Net Profit (Rs. Crores) | 65 | 96 | 136 | 147 | 179 |
| EPS (Rs.) | 7.41 | 10.86 | 14.17 | 15.28 | 18.69 |
Over the past five years, Poly Medicure has exhibited robust financial performance, with steady growth across key metrics. Sales have seen consistent expansion, rising from ₹610 crores in 2019 to ₹1,115 crores in 2023, marking a compounded annual growth rate (CAGR) of 17%. This growth is accompanied by a proportional increase in operating profit, reaching ₹267 crores in 2023. The company has maintained healthy profitability, with net profit climbing from ₹65 crores in 2019 to ₹179 crores in 2023, reflecting a compounded profit growth of 20% over five years.
Notably, the earnings per share (EPS) have also seen a notable uptrend, escalating from ₹7.41 in 2019 to ₹18.69 in 2023. Moreover, Poly Medicure has demonstrated impressive stock price performance, with a CAGR of 48% over the last five years, indicating investor confidence in its growth prospects. Additionally, the company’s return on equity (ROE) has remained consistently high, reflecting its efficient utilization of shareholder funds to generate profits, with an ROE of 15% in the last year.
FAQs
What is Poly Medicure’s current market capitalization?
Poly Medicure’s current market capitalization is ₹15,126 crore.
The current share price target for Poly Medicure is ₹1,576 as of April 1st, 2024.
The projected share price target for Poly Medicure in 2025 ranges from ₹1,963.98 to ₹2,347.42.
The projected share price target for Poly Medicure in 2030 ranges from ₹4,108.64 to ₹6,384.03.
What is Poly Medicure’s current price-to-earnings (PE) ratio?
Poly Medicure’s current price-to-earnings (PE) ratio is 60.8.
What is the dividend payout percentage for Poly Medicure?
Poly Medicure’s dividend payout percentage is 0.19%.
What is the compounded profit growth rate for Poly Medicure over the past 3 years?
Poly Medicure’s compounded profit growth rate over the past 3 years is 22%.
How has Poly Medicure’s stock price performed over the last 5 years?
Poly Medicure’s stock price has shown a compounded annual growth rate (CAGR) of 48% over the last 5 years.
What is the company’s return on equity (ROE) for the last year?
Poly Medicure’s return on equity (ROE) for the last year is 15%.
What is the company’s face value?
Poly Medicure’s face value is ₹5.00.
How has Poly Medicure’s EPS grown over the past 5 years?
Poly Medicure’s EPS has grown from ₹7.41 in 2019 to ₹18.69 in 2023, reflecting steady growth over the period.
Also Read
- JK Lakshmi Cement Share Price Target 2024, 2025, 2026 To 2030
- JK Tyre and Industries Share Price Target 2024, 2025, 2026 to 2030: Can it touch 1000 INR?
- JAMES WARREN TEA SHARE PRICE TARGET 2024, 2025, 2026 TO 2030
Poly Medicure Limited emerges as a stalwart in the global healthcare industry, renowned for its commitment to innovation, quality, and extensive product portfolio. With a robust distribution network spanning over 260 distributors and connections to more than 5,000 healthcare institutions, including hospitals and nursing homes, the company ensures widespread accessibility to its medical solutions.
Projected share price targets indicate a promising upward trajectory, reflecting investor confidence in Poly Medicure’s growth prospects. The company’s solid financial performance, marked by a compounded profit growth rate of 19.5% over the last five years and a commendable return on equity (ROE) of 15%, underscores its efficiency in generating profits and maximizing shareholder value.
However, despite its impressive performance, the stock is trading at 11.3 times its book value, indicating potential overvaluation. Poly Medicure’s sustained focus on research and development, exemplified by its R&D facility boasting over 300 patents, ensures continued innovation and competitiveness in the dynamic healthcare landscape. As Poly Medicure continues to navigate growth with innovation, it stands poised to further solidify its position as a key player in the global healthcare arena.
What did we learn?
- 1 About Poly Medicure
- 2 How to Purchase Poly Medicure Shares?
- 3 Poly Medicure Share Price Target 2024 – 2030
- 4 Financial Condition of Poly Medicure: Last 5 years
- 5 FAQs
- 5.1 What is Poly Medicure’s current market capitalization?
- 5.2 What is the current share price target for Poly Medicure?
- 5.3 What is the projected share price target for Poly Medicure in 2025?
- 5.4 What is the projected share price target for Poly Medicure in 2030?
- 5.5 What is Poly Medicure’s current price-to-earnings (PE) ratio?
- 5.6 What is the dividend payout percentage for Poly Medicure?
- 5.7 What is the compounded profit growth rate for Poly Medicure over the past 3 years?
- 5.8 How has Poly Medicure’s stock price performed over the last 5 years?
- 5.9 What is the company’s return on equity (ROE) for the last year?
- 5.10 What is the company’s face value?
- 5.11 How has Poly Medicure’s EPS grown over the past 5 years?
- 6 Conclusion: Poly Medicure Limited: Navigating Growth with Innovation
